Table 1. SAR and in Vitro ADME/DMPK Data for Disubstituted 5-Arylbenzimidazolones.
Cmpd | X | R1 | R2 | GluA1/γ-8 pIC50a | GluA1/γ-2 pIC50b | HLM/RLM stabilityc | MDCK-MDR1d (B-A)/(A-B) × 10–6cm/s | Solubility (SGF/FaSSIF)e (μM) | PPB,fub (h/r)f | cLogP | LLE |
---|---|---|---|---|---|---|---|---|---|---|---|
6 | CH | CH3 | CH3 | 6.8 ± 0.1 | <5 | 0.3/0.5 | 34/42 | 5/276 | 2.1/3.7 | 3.4 | 3.4 |
7 | CH | Cl | CH3 | 7.3 ± 0.3 | <5 | <0.3/0.6 | 32/25 | <4/146 | 0.9/1.4 | 3.7 | 3.6 |
8 | CH | Cl | cPr | 8.2 ± 0.2 | <5 | <0.3/0.5 | 18/10 | <4/90 | 0.2/1.5 | 4.1 | 4.1 |
9 | CH | Cl | Cl | 7.3 ± 0.2 | <5 | <0.3/0.3 | 49/26 | <4/69 | 0.5/0.6 | 3.9 | 3.4 |
10 | N | Cl | Cl | 6.6 ± 0.2 | <5 | <0.3/<0.2 | 83/16 | 42/52 | 2.9/2.7 | 2.6 | 3.9 |
11 | CH | Cl | CN | 6.6 ± 0.3 | <5 | <0.3/<0.2 | 70/14 | <4/5 | 5.1/7.1 | 2.9 | 3.7 |
12 | CH | Cl | CH2CN | 8.0 ± 0.41 | <51 | <0.3/0.6 | 70/6.6 | 26/230 | 2.7/7.6 | 2.6 | 5.4 |
13 | CH | Cl | OCH3 | 6.9 ± 0.2 | <5 | 0.3/0.6 | 50/26 | 19/142 | 3.9/6.5 | 3.0 | 3.8 |
3 | CH | Cl | OCF3 | 8.3 ± 0.31 | <51 | <0.3/0.3 | 24/22 | <4/74 | 0.3/1.5 | 4.1 | 4.2 |
pIC50 measured in a FLIPR assay using HEK-293 cells expressing a human GluA1o-γ-8 fusion construct; all data are the result of at least three assays run in triplicate with the mean and standard deviation reported.
pIC50 measured in a FLIPR assay using HEK-293 cells expressing human GluA1-flop cotransfected with γ-2.
Stability in human and rat liver microsomes at 1 μM; data are reported as extraction ratios.
Apparent permeability in Madin–Darby canine kidney cells transfected with the MDR1 (P-gp) gene.
Thermodynamic solubility in simulated gastric fluid (pH = 1.6) and fasted state simulated intestinal fluid (pH = 6.5).
Human and rat plasma protein binding reported as fraction unbound (fub) at 1 μM. Details for all assay conditions are provided in the Supporting Information.